Key result
MMP-9 ablation attenuates cardiac fibrosis and improves left ventricular function in dystrophic mice.
Why the study?
Does genetic ablation of MMP-9 prevent cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy?
Does genetic ablation of MMP-9 prevent cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy?
Genetic ablation of MMP-9 attenuates cardiac injury and improves heart function in a mouse model of Duchenne muscular dystrophy, suggesting MMP-9 and osteopontin as potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for MMP-9 inhibition in Duchenne cardiomyopathy; should not yet change clinical practice.
Duchenne muscular dystrophy (DMD), caused by mutations in the dystrophin gene, is a common and lethal form of muscular dystrophy. With progressive disease, most patients succumb to death from respiratory or heart failure, or both. However, the mechanisms, especially those governing cardiac inflammation and fibrosis in DMD, remain less understood. Matrix metalloproteinase (MMPs) are a group of extracellular matrix proteases involved in tissue remodeling in both physiologic and pathophysiologic conditions. Previous studies have shown that MMP-9 exacerbates myopathy in dystrophin-deficient mdx mice. However, the role and the mechanisms of action of MMP-9 in cardiac tissue and the biochemical mechanisms leading to increased levels of MMP-9 in mdx mice remain unknown. Our results demonstrate that the levels of MMP-9 are increased in the heart of mdx mice. Genetic ablation of MMP-9 attenuated cardiac injury, left ventricle dilation, and fibrosis in 1-y-old mdx mice. Echocardiography measurements showed improved heart function in Mmp9-deficient mdx mice. Deletion of the Mmp9 gene diminished the activation of ERK1/2 and Akt kinase in the heart of mdx mice. Ablation of MMP-9 also suppressed the expression of MMP-3 and MMP-12 in the heart of mdx mice. Finally, our experiments have revealed that osteopontin, an important immunomodulator, contributes to the increased amounts of MMP-9 in cardiac and skeletal muscle of mdx mice. This study provides a novel mechanism for development of cardiac dysfunction and suggests that MMP-9 and OPN are important therapeutic targets to mitigating cardiac abnormalities in patients with DMD.
No takes yet. Share an insight, caveat, or question.
Dahiya et al. (2011) studied Duchenne muscular dystrophy cardiomyopathy (mdx mouse model). Genetic ablation of MMP-9 (Mmp9-/-) and anti-osteopontin neutralizing antibody vs. mdx/Mmp9+/+ mice and isotype control (200 μg/ml) was evaluated on Cardiac injury, fibrosis, and left ventricular function (fractional shortening, LVIDd, LVPWd) (p=<0.05). Genetic ablation of MMP-9 attenuated cardiac fibrosis, left ventricular dilation, and improved fractional shortening in 1-year-old mdx mice.
Synapse has enriched 10 related papers. Consider them for comparative context: